Korean J Ophthalmol > Volume 35(1); 2021 > Article |
|
This study was presented at oral presentation section of 15th International Symposium in Ocular Pharmacology and Therapeutics on November 7-9, 2019 in Valencia, Spain.
Conflict of Interest
No potential conflict of interest relevant to this article was reported.
Parameter | Value | p-value |
---|---|---|
IOP (mmHg) | ||
IOP-b | 16.17 ± 2.71 | NA |
IOP-1 | 18.15 ± 3.44 | p1 < 0.001* |
IOP-2 | 18.52 ± 4.03 | p2 < 0.001* |
IOP-3 | 18.39 ± 3.93 | p3 < 0.001* |
IOP-4 | 17.19 ± 3.40 | p4 < 0.001* |
p-value† | <0.001 | |
CCT (μm) | ||
CCT-b | 555.39 ± 31.90 | NA |
CCT-1 | 555.00 ± 30.83 | p1 = 0.191* |
CCT-2 | 555.00 ± 30.92 | p2 = 0.446* |
CCT-3 | 555.50 ± 30.83 | p3 = 0.401* |
CCT-4 | 555.00 ± 31.68 | p4 = 0.704* |
p-value † | 0.117 |
IOP = intraocular pressure; CCT = central corneal thickness; HBOT = hyperbaric oxygen therapy; NA = not available; b = baseline value; 1 = value after 10th session of HBOT; 2 = value after 20th session of HBOT; 3 = value after 30th session of HBOT; 4 = value after 3 months of last session of HBOT; p1 = comparison of baseline and after the 10th session of HBOT; p2 = comparison of baseline and after the 20th session of HBOT; p3 = comparison of baseline and after the 30th session of HBOT; p4 = comparison of baseline and after 3 months of the last session of HBOT.
Parameter | Value | p-value |
---|---|---|
RNFL (μm) | ||
RNFL-IN-b | 105.86 ± 30.40 | NA |
RNFL-IN-1 | 104.56 ± 29.24 | p1 = 0.124* |
RNFL-IN-2 | 105.02 ± 30.63 | p2 = 0.351* |
RNFL-IN-3 | 105.28 ± 30.33 | p3 = 0.606* |
RNFL-IN-4 | 104.41 ± 29.39 | p4 = 0.370* |
p-value † | 0.096 | |
RNFL-IT-b | 116.80 ± 26.46 | NA |
RNFL-IT-1 | 117.17 ± 22.30 | p1 = 0.661* |
RNFL-IT-2 | 118.19 ± 26.74 | p2 = 0.363* |
RNFL-IT-3 | 117.52 ± 23.34 | p3 = 0.485* |
RNFL-IT-4 | 116.26 ± 22.50 | p4 = 0.571* |
p-value † | 0.07 | |
RNFL-SN-b | 100.28 ± 26.68 | NA |
RNFL-SN-1 | 100.60 ± 25.26 | p1 = 0.697* |
RNFL-SN-2 | 99.47 ± 27.22 | p2 = 0.477* |
RNFL-SN-3 | 101.41 ± 26.49 | p3 = 0.289* |
RNFL-SN-4 | 100.95 ± 26.71 | p4 = 0.455* |
p-value † | 0.904 | |
RNFL-ST-b | 111.78 ± 25.04 | NA |
RNFL-ST-1 | 112.28 ± 25.39 | p1 = 0.777* |
RNFL-ST-2 | 112.45 ± 24.79 | p2 = 0.601* |
RNFL-ST-3 | 112.36 ± 25.10 | p3 = 0.691* |
RNFL-ST-4 | 111.73 ± 25.00 | p4 = 0.270* |
p-value † | 0.096 | |
RNFL-T-b | 70.50 ± 10.13 | NA |
RNFL-T-1 | 71.32 ± 10.28 | p1 = 0.113* |
RNFL-T-2 | 69.56 ± 8.27 | p2 = 0.313* |
RNFL-T-3 | 70.50 ± 9.36 | p3 = 0.818* |
RNFL-T-4 | 70.26 ± 10.28 | p4 = 0.196* |
p-value † | 0.02 | |
RNFL-N-b | 66.71 ± 11.29 | NA |
RNFL-N-1 | 66.63 ± 10.25 | p1 = 0.882* |
RNFL-N-2 | 66.30 ± 11.01 | p2 = 0.411* |
RNFL-N-3 | 66.78 ± 10.34 | p3 = 0.775* |
RNFL-N-4 | 66.45 ± 10.30 | p4 = 0.237* |
p-value † | 0.248 |
RNFL = retinal nerve fiber layer; HBOT = hyperbaric oxygen therapy; NA = not available; IN = inferonasal; IT = inferotemporal; SN = superionasal; ST = superiotemporal; N = nasal; T = temporal; b = baseline measurement; 1 = measurements after 10th session of HBOT; 2 = measurements after 20th session of HBOT; 3 = measurement after 30th session of HBOT; 4 = measurements after threemonth of last session of HBOT; p1 = comparison of baseline and after the 10th session of HBOT; p2 = comparison of baseline and after the 20th session of HBOT; p3 = comparison of baseline and after the 30th session of HBOT; p4 = comparison of baseline and after 3 months of the last session of HBOT.
IOP value (mmHg) | HbA1c (mg/dL) | p-value* | ||
---|---|---|---|---|
|
||||
≤7.0 (n = 17) | 7.0< ≤7.5 (n = 17) | >7.5 (n = 12) | ||
IOP-b | 17 (10-21) | 16 (13-19) | 16 (14-21) | 0.694 |
IOP-1 | 17 (13-22) | 17 (14-21) | 22 (14-28) | 0.029 |
IOP-2 | 17 (13-22) | 17 (14-22) | 21.5 (14-28) | 0.018 |
IOP-3 | 17 (13-22) | 17 (14-22) | 22.5 (17-27) | 0.049 |
IOP-4 | 16 (12-21) | 16 (14-21) | 19 (14-21) | 0.61 |